{"product_id":"hla-dra-antibody-bha17128701","title":"HLA-DRA Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eHLA-DRA Antibody is an antibody targeting \u003cstrong\u003eHLA-DRA\u003c\/strong\u003e, raised in \u003cstrong\u003eMouse\u003c\/strong\u003e for protein detection and localization studies where these specifications are required.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e HLA-DRA.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Monoclonal (mouse origin); Clone 5B13F7; Mouse IgG2b.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eConjugate\/label:\u003c\/strong\u003e Unconjugated (affects detection chemistry and multiplex compatibility).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eListed applications:\u003c\/strong\u003e WB, IHC-P, FACS (refer to on-page specifications for application-specific guidance).\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eHLA class II histocompatibility antigen, DR alpha chain is a protein that in humans is encoded by the HLA-DRA gene. It is mapped to 6p21.32. HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eComparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).\u003c\/li\u003e \u003cli\u003eSubcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.\u003c\/li\u003e \u003cli\u003eIntegration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eImmunohistochemistry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eFlow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands\/signals accordingly.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eEpitope context:\u003c\/strong\u003e binding can depend on protein conformation and sample processing; region information in the title\/immunogen can help anticipate what may be detected.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies differences:\u003c\/strong\u003e predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include negative controls (no-primary\/isotype), and where possible genetic controls (KO\/KD) or independent antibodies to strengthen conclusions.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry P01903 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/P01903 - Gene search: HLA-DRA — NCBI Gene — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=HLA-DRA - Ensembl search: HLA-DRA — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=HLA-DRA - PubMed search: HLA-DRA antibody — PubMed — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=HLA-DRA+antibody - Reactome search: HLA-DRA — Reactome — https:\/\/reactome.org\/content\/query?q=HLA-DRA --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53046429647213,"sku":"RQ7131","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_a9cb89fd-61f5-4561-8233-a410d90c95f1.jpg?v=1772000586","url":"https:\/\/www.ebiohippo.com\/products\/hla-dra-antibody-bha17128701","provider":"BioHippo","version":"1.0","type":"link"}